Guglielmo Verona
Overview
Explore the profile of Guglielmo Verona including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
359
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Raheja S, Verona G, Florent P, Rendell N, Nocerino P, Ellemerich S, et al.
Amyloid
. 2024 Dec;
32(1):46-53.
PMID: 39676281
Background: Proteomics is routinely used to type clinical amyloid deposits, and offers additional benefit of identifying genetic variants, which can be diagnostically useful. Reviewing the proteomics data for ATTR patients...
2.
Fontana M, Gillmore J, Verona G
JACC Basic Transl Sci
. 2024 Oct;
9(9):1101-1103.
PMID: 39444933
No abstract available.
3.
Lavatelli F, Natalello A, Marchese L, Ami D, Corazza A, Raimondi S, et al.
J Biol Chem
. 2024 Mar;
300(4):107174.
PMID: 38499153
AL amyloidosis is a life-threatening disease caused by deposition of immunoglobulin light chains. While the mechanisms underlying light chains amyloidogenesis in vivo remain unclear, several studies have highlighted the role...
4.
Verona G, Raimondi S, Canetti D, Mangione P, Marchese L, Corazza A, et al.
Protein Sci
. 2024 Feb;
33(3):e4931.
PMID: 38380705
The mechanism that converts native human transthyretin into amyloid fibrils in vivo is still a debated and controversial issue. Commonly, non-physiological conditions of pH, temperature, or organic solvents are used...
5.
Raimondi S, Faravelli G, Nocerino P, Mondani V, Baruffaldi A, Marchese L, et al.
FASEB Bioadv
. 2023 Nov;
5(11):484-505.
PMID: 37936921
β-microglobulin (β-m) is a plasma protein derived from physiological shedding of the class I major histocompatibility complex (MHCI), causing human systemic amyloidosis either due to persistently high concentrations of the...
6.
Fontana M, Gilbertson J, Verona G, Riefolo M, Slamova I, Leone O, et al.
N Engl J Med
. 2023 Jun;
388(23):2199-2201.
PMID: 37285532
No abstract available.
7.
Izco M, Schleef M, Schmeer M, Carlos E, Verona G, Alvarez-Erviti L
Pharmaceutics
. 2023 Apr;
15(4).
PMID: 37111717
The development of effective disease-modifying therapies to halt Parkinson's disease (PD) progression is required. In a subtype of PD patients, alpha-synuclein pathology may start in the enteric nervous system (ENS)...
8.
Cantarutti C, Mimmi M, Verona G, Mandaliti W, Taylor G, Mangione P, et al.
Biomolecules
. 2022 Aug;
12(8).
PMID: 36008960
The plasma protein transthyretin (TTR), a transporter for thyroid hormones and retinol in plasma and cerebrospinal fluid, is responsible for the second most common type of systemic (ATTR) amyloidosis either...
9.
Faravelli G, Mondani V, Mangione P, Raimondi S, Marchese L, Lavatelli F, et al.
Front Mol Biosci
. 2022 Mar;
9:830006.
PMID: 35237660
The globular to fibrillar transition of proteins represents a key pathogenic event in the development of amyloid diseases. Although systemic amyloidoses share the common characteristic of amyloid deposition in the...
10.
Slamova I, Adib R, Ellmerich S, Golos M, Gilbertson J, Botcher N, et al.
Nat Commun
. 2021 Dec;
12(1):7112.
PMID: 34876572
Cardiac ATTR amyloidosis, a serious but much under-diagnosed form of cardiomyopathy, is caused by deposition of amyloid fibrils derived from the plasma protein transthyretin (TTR), but its pathogenesis is poorly...